Trius prices $29.9M offering; NICE calls for exposing trial data;

 @FierceBiotech: NuPathe jumps on FDA's OK for migraine drug. News | Follow @FierceBiotech

@JohnCFierce: VC ends '12 on a high note, outlook ranges from tough to terrific. More | Follow @JohnCFierce

@RyanMFierce: Does anyone know how much total funding (VC, corp., foundation) went into biotech? Still, $800M off in 2012 from '11 on the VC front. Yikes. | Follow @RyanMFierce

> Trius Therapeutics ($TSRX), which has a lead antibiotic against MRSA in Phase III development, has priced shares for a public offering worth $29.9 million. Release

> The U.K. drug-pricing watchdog NICE is likely to encounter resistance from pharma with its call for all clinical trial data to be published. Article | More

> With tech from the University of Miami, Biscayne Pharmaceuticals has grabbed a $1.5 million financing to research new growth hormone drugs. Release

Medical Device News

 @FierceMedDev: Medical device VC cash plunged 13% in 2012. Report | Follow @FierceMedDev

 @DamianFierce: So, is $LIFE looking to sell itself? This PR is ominous. Release | Follow @DamianFierce

> Trauson's shares jump 41% on news of Stryker's $764M offer. Item

> GI Dynamics launches trial targeting FDA approval. Story

> FDA wants feedback on tighter hip-implant regs. News

Pharma News

@FiercePharma: Not as good for branded pharma, CHMP also OK'd generic versions of Forest's Namenda + Boehringer's Micardis. More | Follow @FiercePharma

 @AlisonBFierce: Roche said U.S. regulators will allow it to begin selling the company's reserve stock of adult Tamiflu capsules. News | Follow @AlisonBFierce

@EricPFierce: Costco jumps into pharmacy benefits, bringing a new player to the table for drug companies to think about. Report | Follow @EricPFierce

> Pfizer's Bosulif set for greater sales with EMA approval. Article

> Pfizer sets share price for animal health spinoff. Report

> FTC says pay-to-delay getting worse; GpHA says nonsense. News

And Finally… Acorda Therapeutics ($ACOR) CEO Ron Cohen wants the U.S. to alter its tax code to cater to biotech investment. Forbes column

 

 

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.